Navigation Links
Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
Date:3/3/2009

Infectious Diseases Company Featured on March 9th and 10th, 2009, at BioSquare Meeting in France, and March 17, 2009, at BioEurope in Italy

ROCKVILLE, Md., March 3 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products for infectious diseases of epidemic potential has announced that Alan Klein, Sequella Executive Vice President for Corporate Development, will participate in a Panel at the BioSquare 2009 Meeting at the Lyon Congress Center in Lyon, France. The Panel, entitled New Antibiotherapies for Tomorrow, will be held from 10:45 AM to 12:00 noon on March 9, 2009. The presentation will address antibiotic strategies of the 21st century and highlights both the most advanced and successful approaches and the characteristics of future opportunities.

Mr. Klein will also present at the same meeting on Tuesday, March 10, from 10:15 to 11:00 AM in Room St. Clair 2, 2nd floor, as part of the CNS & Infectious Diseases section of BioSquare 2009 at the Lyon Congress Center in Lyon, France.

Sequella will also present on March 17, 2009 at 5:00 PM in Room Yellow 3, Level 1, of the Infectious Diseases section at BioEurope Spring 2009 at the Milano Convention Centre in Milan, Italy.

"We look forward to participating in both of these European conferences and presenting new information regarding the progress of our product portfolio, while continuing partnership discussions that will appropriately monetize our assets," said Mr. Klein. To learn more about Sequella or their presentations at BioSquare or the BioEurope Spring conference, visit www.sequella.com.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.


'/>"/>
SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
4. New Company to Develop Nutritional Interventions Against Chronic Inflammatory and Infectious Diseases
5. Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
6. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
7. Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents
8. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
9. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
10. Steve Davis Joins Infectious Disease Research Institute (IDRI) as Interim CEO
11. Collaborative Software Initiative Addresses State Governments Requirements for Meeting Infectious Disease Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
Breaking Biology News(10 mins):